Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

SUNITINIB VIVANTA 25 MG CÁPSULAS DURAS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/SUNITINIB VIVANTA 25 MG CÁPSULAS DURAS EFG

Approved

STANDARD

SUNITINIB VIVANTA 25 MG CÁPSULAS DURAS EFG

Vivanta Generics S.R.O.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Apr 21, 2022
Approval ID: 95c2ec4da0d3aeb2
Company: Vivanta Generics S.R.O.
Type: Standard

Approval Details

Approval Id: 95c2ec4da0d3aeb2
Drug Cima Aemps Name: SUNITINIB VIVANTA 25 MG CÁPSULAS DURAS EFG
Register Number: 86910
Holder Company Name: Vivanta Generics S.R.O.
Marketing Company Name: Vivanta Generics S.R.O. Sucursal En Espana
Authorization Date: 2022-04-21
Dosage Form: CÁPSULA DURA
Dose: 25 mg
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: Yes
Company Name: Vivanta Generics S.R.O.

Active Ingredients

SUNITINIB MALATO

33,41 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Apr 21, 2022

Approval ID

95c2ec4da0d3aeb2

Type

Standard

Back to CIMA-AEMPS Approvals